glp-1 receptor agonists and sglt2 inhibitors inhibitors: a couple at last? Real-World Evidence for GLP-1 Receptor

Randomized controlled trials (RCTs) comparing insulin with established GLP-1 RAs, DPP-4is, or SGLT-2is were included

A reminder that their story doesnt start in Hollywood

Discover dual vs

Dan McKees proposed fiscal year 2027 budget would remove GLP-1 drugs from Rhode Islands Medicaid formulary for weight loss, saving $6.3 million in general revenue

Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA

In summary, GLP-1 drugs offer significant advantages for individuals with type 2 diabetes or weight management concerns